Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/18/21 (What's New)

Summary

  • Virologically suppressed patients with a high risk of cardiovascular disease and nephrotoxicity may need to switch to a new regimen that excludes or limits both ritonavir and NRTIs
  • Switching to a Boosted PI Plus Lamivudine

Action required